Cigna will cap out-of-pocket costs at $200 per month for patients using the weight-loss drugs Wegovy and Zepbound through an add-on to its pharmacy benefit management plans, the company announced on ...

Cigna's pharmacy benefits company, Evernorth, reached pricing deals with Eli Lilly and Novo Nordisk to reduce expenses and provide wider employer access to GLP-1 weight-loss treatments Wegovy and ...

The new weight-loss option will cut what the plan sponsors pay as well as what the patients pay, Cigna’s PBM Evernorth says. Wegovy semaglutide injection pens. Credit: K KStock/Adobe Stock ...

Cigna’s pharmacy benefits unit Evernorth said the deal will bring prices down for employers and their workers.

The Cigna unit positioned the initiative as a cheaper alternative to cash-pay programs. Wegovy maker Novo Nordisk and Zepbound manufacturer Eli Lilly directly sell their drugs to certain patients ...

NEW YORK, May 21 (Reuters) - Cigna (CI.N), opens new tab will cap out-of-pocket costs at $200 per month for patients using the weight-loss drugs Wegovy and Zepbound through an add-on to its ...

Only half of health insurer Cigna's clients currently cover the popular GLP-1 weight loss drugs Wegovy and Zepbound because of their high costs. But the company's pharmacy benefits unit Evernorth ...

While Cigna would not discuss the actual discounts ... gotten between 30% to 50% below the drugs' list price. While Novo's Wegovy lists for $1,350 per month, in March the average net price for ...